3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
48
fludarabine phosphate
28
Filgrastim
27
Radiotherapy
26
Antilymphocyte Serum
26
Busulfan
24
Cyclosporine
23
Peripheral Blood Stem Cell Transplantation
19
Mycophenolic Acid
18
Cord Blood Stem Cell Transplantation
17
Methylprednisolone
16
Methotrexate
16
Melphalan
15
Etoposide
15
Tacrolimus
12
Whole-Body Irradiation
11
Cytarabine
9
Thiotepa
6
Vincristine
5
Psychiatric Rehabilitation
5
sargramostim
4
aldesleukin
4
Sirolimus
4
Leucovorin
4
Granulocyte Colony-Stimulating Factor
4
fludarabine
3
Prednisone
3
Early Intervention, Educational
3
Daunorubicin
3
glucarpidase
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia
×
Interleukin-15
×
Sarcoma
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled